Acrivon Therapeutics
ACRV on Nasdaq. Market value $62m.
Should I look at this?
Look carefully before going further
Why it could be worth it
Nothing stands out yet.
What to watch out for
Read the warning sign in its own filings
This is not advice.
Who owns it
None of the long-term investors we follow own it. 46 funds in all.
Largest holders overall
- RA Capital Management, L.P.$22mAdded
- Sands Capital Alternatives$4mAdded
- Acadian Asset Management$2mAdded
- Vanguard Capital Management$2mAdded
- Wellington Management Group LLP$2m
- Renaissance Technologies$1m
- TWO Sigma Investments, LP$1mAdded
- Marshall Wace, LLP$946,704Cut
- Bridgeway Capital Management$674,442Added
- Geode Capital Management$472,273Added
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
2 investors own more than 5%.
- at least 28.8%+7.2 pts(filed with 3 related holders)Since 22 April 2026
- Sands Capital Life Sciences Pulse Fund II, L.P.Passive investorat least 5.3%−1.5 pts(filed with 2 related holders)Since 30 June 2026
- Citadel Advisors LLCPassive investorSold down below 5%Since 31 March 2026
- Perceptive Advisors LLCPassive investorSold down below 5%Since 2 June 2025
| Holder | Stake | Since | |
|---|---|---|---|
at least 28.8%+7.2 pts (filed with 3 related holders) | 22 April 2026 | ||
Sands Capital Life Sciences Pulse Fund II, L.P. Passive investor | at least 5.3%−1.5 pts (filed with 2 related holders) | 30 June 2026 | |
Citadel Advisors LLC Passive investor | Sold down below 5% | 31 March 2026 | |
Perceptive Advisors LLC Passive investor | Sold down below 5% | 2 June 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 3 insiders bought $114,534 of shares on the open market. 6 sold $45,865.
- Peterson KatharineChief Accounting OfficerSold
- Date
- 17 November 2026
- Shares
- 107
- Price
- $1.45
- Value
- $155
- Miller MaryChief Legal OfficerSold
- Date
- 17 November 2026
- Shares
- 193
- Price
- $1.45
- Value
- $280
- Gamelin ErickChief Development OfficerSold
- Date
- 17 November 2026
- Shares
- 416
- Price
- $1.45
- Value
- $603
- Devroe EricChief Operating OfficerSold
- Date
- 17 November 2026
- Shares
- 628
- Price
- $1.45
- Value
- $911
- Blume-Jensen PeterPresident and CEO, DirectorSold
- Date
- 17 November 2026
- Shares
- 1,780
- Price
- $1.45
- Value
- $2,581
- Miller MaryChief Legal OfficerSold
- Date
- 22 October 2026
- Shares
- 513
- Price
- $1.84
- Value
- $944
- Miller MaryChief Legal OfficerSold
- Date
- 5 October 2026
- Shares
- 294
- Price
- $1.99
- Value
- $585
- Blume-Jensen PeterPresident and CEO, DirectorSold
- Date
- 25 August 2026
- Shares
- 14,036
- Price
- $2.21
- Value
- $30,969
- Peterson KatharineChief Accounting OfficerSold
- Date
- 18 August 2026
- Shares
- 101
- Price
- $2.01
- Value
- $203
- Miller MaryChief Legal OfficerSold
- Date
- 18 August 2026
- Shares
- 185
- Price
- $2.01
- Value
- $372
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 17 November 2026 | Peterson Katharine Chief Accounting Officer | Sold | 107 | $1.45 | $155 |
| 17 November 2026 | Miller Mary Chief Legal Officer | Sold | 193 | $1.45 | $280 |
| 17 November 2026 | Gamelin Erick Chief Development Officer | Sold | 416 | $1.45 | $603 |
| 17 November 2026 | Devroe Eric Chief Operating Officer | Sold | 628 | $1.45 | $911 |
| 17 November 2026 | Blume-Jensen Peter President and CEO, Director | Sold | 1,780 | $1.45 | $2,581 |
| 22 October 2026 | Miller Mary Chief Legal Officer | Sold | 513 | $1.84 | $944 |
| 5 October 2026 | Miller Mary Chief Legal Officer | Sold | 294 | $1.99 | $585 |
| 25 August 2026 | Blume-Jensen Peter President and CEO, Director | Sold | 14,036 | $2.21 | $30,969 |
| 18 August 2026 | Peterson Katharine Chief Accounting Officer | Sold | 101 | $2.01 | $203 |
| 18 August 2026 | Miller Mary Chief Legal Officer | Sold | 185 | $2.01 | $372 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in Acrivon Therapeutics’ filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 19 Mar 2026, plus the 10-Q filed 16 Nov 2026 and 6 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“Based on the Company’s current operating plan and existing cash, cash equivalents, and investments, the Company has determined that there is substantial doubt regarding its ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.”
Show the full paragraph
In accordance with Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205- 40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. Based on the Company’s current operating plan and existing cash, cash equivalents, and investments, the Company has determined that there is substantial doubt regarding its ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.
From the 10-Q filed 16 November 2026, Part I, Item 1. Financial Statements. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.